Breast cancer. Malignant neoplasm of breast of unspecified site
Conditions
Interventions
Intervention 1: Intervention group: Crocin along with standard regime will be assigned to intervention group. The daily dose of crocin will be 30 mg during 24 weeks. Intervention 2: Control group: The
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
25 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients with metastatic breast cancer that is measurable Breast cancer patients who have not received any chemotherapy for metastasis
Exclusion criteria
Exclusion criteria: History of any allergy to saffron or its products
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival. Timepoint: One year after the treatment is completed. Method of measurement: Patient follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival. Timepoint: During treatment and after it every 3 months. Method of measurement: criteria of Response evaluation criteria in solid tumors.;Anemia. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of complete blood count.;Neutropenia. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of complete blood count.;Thrombocytopenia. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of complete blood count.;Kidney function. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of BUN and creatinine.;Liver function. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of SGOT and SGPT. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSoodabeh Shahidsales
Mashhad University of Medical Sciences
Outcome results
None listed